ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE ...
Cambridge Network

Clear terminology, faster clinical device development

Bringing a medical device to clinical trial is one of the most significant milestones in any development journey. Yet terms ...

GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson’s Disease

GEN announces approval in the Netherlands to initiate patient enrollment in April 2026 for the Phase II Proof of ...

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent ...

ANANDA PHARMA LTD ("Ananda" or the "Company") : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis

Ananda's CEO, Melissa Sturgess commented: "The personal and societal burden of endometriosis is staggering and it is appalling that more is not being done to find useful treatments for this ...

Oragenics, Inc.: Oragenics Initiates Phase IIa Clinical Trial Site Activation

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar ...

GEN Ilac ve Saglik Urunleri A.S.: GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson's ...

GEN announces approval in the Netherlands to initiate patient enrollment in April 2026 for the Phase II Proof of Concept trial of its novel drug candidate SUL-238, Targeting Mitochondrial Dysfunction ...

Investornewsbreaks Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site For Phase Iia Trial Of ONP-002 In Australia

Initiates First Clinical Site For Phase Iia Trial Of ONP-002 In Australia. Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using ...

HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence Generation

Detailed price information for Healwell AI Inc A Sub Vtg (HWAIF) from The Globe and Mail including charting and trades.
Scientific Research Publishing

Translating AI Ethics into Hospital Operations: A PPTO Framework for Evidence-Based Governance ()

AI Governance, Ethical AI, Healthcare Management, Bias Mitigation, Organizational Frameworks, Responsible AI Share and Cite: Grant, V. and Levasseur, R. (2026) Translating AI Ethics into Hospital ...

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...